Keywords
Last Name
Institution

EUGENIE S KLEINERMAN

TitleProfessor
InstitutionMD Anderson
DepartmentPediatrics
Address7777 Knight Rd
Houston TX 77054-3005
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-30. PMID: 25587555.
      View in: PubMed
    2. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014 Aug 15; 20(16):4200-9. PMID: 24803583.
      View in: PubMed
    3. Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014 Apr; 34(4):1939-45. PMID: 24692729.
      View in: PubMed
    4. Guma SR, Lee DA, Ling Y, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014 Aug; 61(8):1362-8. PMID: 24610870; PMCID: PMC4144337.
    5. Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer. 2014; 13:34. PMID: 24565056; PMCID: PMC3938086.
    6. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014 Mar 15; 74(6):1645-50. PMID: 24448245; PMCID: PMC3959622.
    7. Zhou Z, Yu L, Kleinerman ES. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer. 2014 Feb 15; 120(4):579-88. PMID: 24415532; PMCID: PMC3969734.
    8. Huang G, Nishimoto K, Yang Y, Kleinerman ES. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Adv Exp Med Biol. 2014; 804:203-17. PMID: 24924176.
      View in: PubMed
    9. Kleinerman ES, Mary V, John A. Osteosarcoma: the state of affairs dictates a change. What do we know? Adv Exp Med Biol. 2014; 804:vii-viii. PMID: 25207354.
      View in: PubMed
    10. Hamdan R, Zhou Z, Kleinerman ES. Blocking SDF-1?/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol Cancer Ther. 2014 Feb; 13(2):483-91. PMID: 24282276.
      View in: PubMed
    11. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res. 2015 Mar; 32(3):779-92. PMID: 24203492; PMCID: PMC4014531.
    12. Hollomon MG, Gordon N, Santiago-O'Farrill JM, Kleinerman ES. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer. 2013; 13:500. PMID: 24160177; PMCID: PMC3924338.
    13. Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL, Kleinerman ES. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014 Apr; 61(4):618-26. PMID: 24136885; PMCID: PMC4154381.
    14. Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014 Feb; 61(2):238-44. PMID: 23997016.
      View in: PubMed
    15. Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets. 2013 May; 13(4):411-22. PMID: 23410027; PMCID: PMC3878976.
    16. Koshkina NV, Yang G, Kleinerman ES. Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression. Curr Cancer Drug Targets. 2013 Jan; 13(1):48-56. PMID: 22920438.
      View in: PubMed
    17. Rao-Bindal K, Rao CK, Yu L, Kleinerman ES. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatr Blood Cancer. 2013 Apr; 60(4):575-9. PMID: 23255321; PMCID: PMC3883385.
    18. Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis. 2012; 1:e34. PMID: 23552467.
      View in: PubMed
    19. Rao-Bindal K, Zhou Z, Kleinerman ES. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis. 2012; 3:e369. PMID: 22875006.
      View in: PubMed
    20. Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012 Feb 15; 72(4):908-16. PMID: 22186140; PMCID: PMC3288434.
    21. Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor ?-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012 Jan 1; 72(1):271-81. PMID: 22075555; PMCID: PMC3833671.
    22. Hamdan R, Zhou Z, Kleinerman ES. SDF-1? induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Mol Cancer Res. 2011 Nov; 9(11):1462-70. PMID: 21911740; PMCID: PMC3219839.
    23. Huang G, Zhou Z, Wang H, Kleinerman ES. CAPER-a alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cells. Cancer. 2012 Apr 15; 118(8):2106-16. PMID: 22009261.
      View in: PubMed
    24. Stewart KS, Kleinerman ES. Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. Sarcoma. 2011; 2011:165837. PMID: 21785569; PMCID: PMC3137951.
    25. Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer. 2011 Aug 1; 117(15):3457-67. PMID: 21287529; PMCID: PMC3136583.
    26. Rao-Bindal K, Kleinerman ES. Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma. 2011; 2011:679457. PMID: 21253504.
      View in: PubMed
    27. Zhou Z, Stewart KS, Yu L, Kleinerman ES. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. Angiogenesis. 2011 May; 14(2):125-33. PMID: 21184173.
      View in: PubMed
    28. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood. 2011 Jan 13; 117(2):719-26. PMID: 20944072; PMCID: PMC3031490.
    29. Wang Y, Mandal D, Wang S, Kleinerman ES, Pollock RE, Lev D, Hayes-Jordan A. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer. 2010 Aug 15; 116(16):3892-902. PMID: 20564078.
      View in: PubMed
    30. Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010 Aug; 23(4):189-96. PMID: 20528149; PMCID: PMC3133834.
    31. Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, Anderson PM. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2010 Aug; 23(4):197-206. PMID: 19803732.
      View in: PubMed
    32. Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res. 2010 Aug 1; 16(15):4024-30. PMID: 20576718.
      View in: PubMed
    33. Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Res. 2010 Feb 15; 70(4):1334-43. PMID: 20124484.
      View in: PubMed
    34. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res. 2010 Feb 1; 16(3):848-56. PMID: 20103680.
      View in: PubMed
    35. Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer. 2009 Dec 1; 125(11):2586-94. PMID: 19544560.
      View in: PubMed
    36. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15; 115(22):5339-48. PMID: 19637348; PMCID: PMC2783515.
    37. Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, Lev D, Kleinerman E, Hayes-Jordan A. Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo. 2009 Nov-Dec; 23(6):903-9. PMID: 20023231.
      View in: PubMed
    38. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87. PMID: 19532139; PMCID: PMC2835000.
    39. Huang G, Koshkina NV, Kleinerman ES. Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. Oncol Res. 2009; 18(1):31-9. PMID: 19911702; PMCID: PMC2929182.
    40. Guan H, Zhou Z, Cao Y, Duan X, Kleinerman ES. VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. Oncol Res. 2009; 18(2-3):117-25. PMID: 20066901.
      View in: PubMed
    41. Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res. 2009; 152:497-508. PMID: 20213411.
      View in: PubMed
    42. Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer. 2009 Jan 1; 115(1):13-22. PMID: 19051291.
      View in: PubMed
    43. Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, Kleinerman ES. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer. 2008 Aug 15; 123(4):831-7. PMID: 18537159; PMCID: PMC2587257.
    44. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther. 2008 Jul; 7(7):1807-16. PMID: 18644993; PMCID: PMC2556989.
    45. Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF, Kleinerman ES. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 2008 Jul; 30(7):507-12. PMID: 18797196.
      View in: PubMed
    46. Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res. 2008 Jun; 6(6):929-36. PMID: 18567797.
      View in: PubMed
    47. Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008 Apr 8; 98(7):1250-7. PMID: 18349828; PMCID: PMC2359649.
    48. Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis. 2008; 11(3):257-67. PMID: 18344025.
      View in: PubMed
    49. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 1; 26(4):633-8. PMID: 18235123.
      View in: PubMed
    50. Graat HC, van Beusechem VW, Schagen FH, Witlox MA, Kleinerman ES, Helder MN, Gerritsen WR, Kaspers GJ, Wuisman PI. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer. 2008; 7:9. PMID: 18215325; PMCID: PMC2254437.
    51. Cao Y, Jia SF, Chakravarty G, de Crombrugghe B, Kleinerman ES. The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells. Mol Cancer Res. 2008 Jan; 6(1):119-26. PMID: 18234967; PMCID: PMC2929177.
    52. Jia SF, Guan H, Duan X, Kleinerman ES. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 2008; 7(2):89-97. PMID: 18771083.
      View in: PubMed
    53. Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol. 2007 Dec; 29(12):815-21. PMID: 18090928.
      View in: PubMed
    54. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother. 2008 Feb; 52(2):716-8. PMID: 17984233; PMCID: PMC2224773.
    55. Zhou Z, Reddy K, Guan H, Kleinerman ES. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res. 2007 Nov; 5(11):1125-32. PMID: 18025258.
      View in: PubMed
    56. Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer. 2007 Oct 1; 110(7):1568-77. PMID: 17694551.
      View in: PubMed
    57. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007 Oct; 5(10):991-9. PMID: 17951400.
      View in: PubMed
    58. Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res. 2007 Aug 15; 13(16):4867-73. PMID: 17699866.
      View in: PubMed
    59. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007 Aug 1; 13(15 Pt 1):4503-10. PMID: 17671136.
      View in: PubMed
    60. Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, Lessnick SL, Denny CT. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res. 2007 Jul 15; 67(14):6675-84. PMID: 17638877.
      View in: PubMed
    61. De Angulo G, Hernandez M, Morales-Arias J, Herzog CE, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol. 2007 Jan; 29(1):48-52. PMID: 17230066.
      View in: PubMed
    62. Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer. 2006 Aug 15; 119(4):839-46. PMID: 16557578.
      View in: PubMed
    63. Jia SF, Duan X, Worth LL, Guan H, Kleinerman ES. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma. Cancer Gene Ther. 2006 Oct; 13(10):948-57. PMID: 16763609.
      View in: PubMed
    64. Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer. 2006 Mar 15; 106(6):1382-8. PMID: 16453328.
      View in: PubMed
    65. Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res. 2005 Dec; 3(12):685-91. PMID: 16380506.
      View in: PubMed
    66. Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol. 2005 Nov; 27(11):611-5. PMID: 16282894.
      View in: PubMed
    67. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005 Oct 15; 104(8):1713-20. PMID: 16121404.
      View in: PubMed
    68. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005 Sep 1; 116(3):458-63. PMID: 15800950.
      View in: PubMed
    69. Zhou Z, Guan H, Kleinerman ES. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity. Mol Cancer Res. 2005 May; 3(5):271-5. PMID: 15886298.
      View in: PubMed
    70. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res. 2005 Apr 1; 11(7):2662-9. PMID: 15814647.
      View in: PubMed
    71. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11. PMID: 15774791.
      View in: PubMed
    72. Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res. 2005 Mar 1; 11(5):2008-17. PMID: 15756027.
      View in: PubMed
    73. Cao Y, Zhou Z, de Crombrugghe B, Nakashima K, Guan H, Duan X, Jia SF, Kleinerman ES. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res. 2005 Feb 15; 65(4):1124-8. PMID: 15734992.
      View in: PubMed
    74. Asano T, Kleinerman ES, Zwelling LA, Zhou Z, Fukunaga Y. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells. Acta Oncol. 2005; 44(3):240-7. PMID: 16076696.
      View in: PubMed
    75. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res. 2004 Dec 1; 10(23):8114-9. PMID: 15585647.
      View in: PubMed
    76. Duan X, Zhou Z, Jia SF, Colvin M, Lafleur EA, Kleinerman ES. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res. 2004 Jan 15; 10(2):777-83. PMID: 14760101.
      View in: PubMed
    77. Duan X, Jia SF, Zhou Z, Langley RR, Bolontrade MF, Kleinerman ES. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis. 2004; 21(8):747-53. PMID: 16035619.
      View in: PubMed
    78. Zhou Z, Zhou RR, Guan H, Bucana CD, Kleinerman ES. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther. 2003 Dec; 2(12):1313-9. PMID: 14707272.
      View in: PubMed
    79. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15; 9(15):5442-53. PMID: 14654523.
      View in: PubMed
    80. Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res. 2003 Aug 15; 9(9):3462-8. PMID: 12960138.
      View in: PubMed
    81. Marco RA, Díaz-Montero CM, Wygant JN, Kleinerman ES, McIntyre BW. Alpha 4 integrin increases anoikis of human osteosarcoma cells. J Cell Biochem. 2003 Apr 1; 88(5):1038-47. PMID: 12616540.
      View in: PubMed
    82. Gautam A, Waldrep JC, Kleinerman ES, Xu B, Fung YK, T'Ang A, Densmore CL. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. Methods Mol Med. 2003; 75:607-18. PMID: 12407767.
      View in: PubMed
    83. Jia SF, Zhou RR, Kleinerman ES. Nude mouse lung metastases models of osteosarcoma and Ewing's sarcoma for evaluating new therapeutic strategies. Methods Mol Med. 2003; 74:495-505. PMID: 12415717.
      View in: PubMed
    84. Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. Clin Cancer Res. 2002 Nov; 8(11):3622-7. PMID: 12429654.
      View in: PubMed
    85. Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep. 2002 Jul-Aug; 9(4):823-7. PMID: 12066216.
      View in: PubMed
    86. Zhou RR, Jia SF, Zhou Z, Wang Y, Bucana CD, Kleinerman ES. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther. 2002 May; 9(5):407-13. PMID: 11961663.
      View in: PubMed
    87. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002 Mar; 9(3):260-6. PMID: 11896442.
      View in: PubMed
    88. Jia SF, Worth LL, Turan M, Duan Xp XP, Kleinerman ES. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drugs. 2002 Feb; 13(2):155-61. PMID: 11901308.
      View in: PubMed
    89. Jia SF, Zwelling LA, McWatters A, An T, Kleinerman ES. Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. J Exp Ther Oncol. 2002 Jan-Feb; 2(1):27-36. PMID: 12415617.
      View in: PubMed
    90. Densmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T'Ang A, Knight V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 2001 Sep; 8(9):619-27. PMID: 11593330.
      View in: PubMed
    91. Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer. 2001 Sep 1; 85(5):747-51. PMID: 11531262.
      View in: PubMed
    92. Worth LL, Jeha SS, Kleinerman ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug; 15(4):723-40, ix. PMID: 11676281.
      View in: PubMed
    93. Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res. 2001 May 15; 61(10):4066-71. PMID: 11358827.
      View in: PubMed
    94. Zhou Z, Jia SF, Hung MC, Kleinerman ES. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res. 2001 Apr 15; 61(8):3394-8. PMID: 11309298.
      View in: PubMed
    95. Worth LL, Jia SF, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res. 2000 Sep; 6(9):3713-8. PMID: 10999765.
      View in: PubMed
    96. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res. 2000 Jul; 6(7):2876-80. PMID: 10914737.
      View in: PubMed
    97. Knight V, Koshkina N, Waldrep C, Giovanella BC, Kleinerman E, Gilbert B. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Trans Am Clin Climatol Assoc. 2000; 111:135-45. PMID: 10881338; PMCID: PMC2194367.
    98. Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci. 2000; 922:151-63. PMID: 11193890.
      View in: PubMed
    99. Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res. 1999 Sep 15; 59(18):4618-24. PMID: 10493516.
      View in: PubMed
    100. Worth LL, Jia SF, An T, Kleinerman ES. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother. 1999 Sep; 48(6):312-20. PMID: 10473806.
      View in: PubMed
    101. Jia SF, An T, Worth L, Kleinerman ES. Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res. 1999 Jun; 19(6):617-24. PMID: 10433362.
      View in: PubMed
    102. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999; 17(6):501-6. PMID: 10763916.
      View in: PubMed
    103. Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm. 1998 Oct; 13(5):363-8. PMID: 10851426.
      View in: PubMed
    104. Worth LL, Jaffe N, Benjamin RS, Papadopoulos NE, Patel S, Raymond AK, Jia SF, Rodriguez C, Gano J, Gianan MA, Kleinerman ES. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res. 1997 Oct; 3(10):1721-9. PMID: 9815556.
      View in: PubMed
    105. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J. 1996 Oct 1; 319 ( Pt 1):307-13. PMID: 8870683; PMCID: PMC1217769.
    106. Asano T, Zwelling LA, An T, McWatters A, Herzog CE, Mayes J, Loughlin SM, Kleinerman ES. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer. 1996 Jun; 73(11):1373-80. PMID: 8645582; PMCID: PMC2074495.
    107. Asano T, An T, Jia SF, Kleinerman ES. Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity. J Leukoc Biol. 1996 Jun; 59(6):916-24. PMID: 8691078.
      View in: PubMed
    108. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 May; 19(3):206-17. PMID: 8811495.
      View in: PubMed
    109. Glass RJ, Eftekhari F, Kleinerman ES, Jaffe N, Nachman J. Osteosarcoma metastatic to the pancreas in young patients. Clin Radiol. 1996 Apr; 51(4):293-4. PMID: 8617044.
      View in: PubMed
    110. Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res. 1996; 8(3):101-10. PMID: 8823806.
      View in: PubMed
    111. Herzog CE, Zwelling LA, McWatters A, Kleinerman ES. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Clin Cancer Res. 1995 Nov; 1(11):1391-7. PMID: 9815936.
      View in: PubMed
    112. Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug; 9(4):927-38. PMID: 7490249.
      View in: PubMed
    113. Gano JB, Kleinerman ES. Liposomal MTP-PE: a promising new biologic response modifier. Oncol Nurs Forum. 1995 Jun; 22(5):809-16. PMID: 7675688.
      View in: PubMed
    114. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995 Apr; 17(3):181-93. PMID: 7613644.
      View in: PubMed
    115. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr; 18(2):93-9. PMID: 7900714.
      View in: PubMed
    116. Gano JB, Kleinerman ES. Administration of liposomal MTP-PE by the local physician: the role of the research nurse. Cancer Pract. 1995 Jan-Feb; 3(1):42-6. PMID: 7704060.
      View in: PubMed
    117. Risin D, Kleinerman ES, Umezu Y, Pizzini RP, Balch CM, Pellis NR. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunol Immunother. 1995 Jan; 40(1):57-64. PMID: 7828168.
      View in: PubMed
    118. Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res. 1995; 7(5):253-7. PMID: 8534931.
      View in: PubMed
    119. Gano JB, Kleinerman ES. Liposomal MTP-PE. J Pediatr Oncol Nurs. 1994 Oct; 11(4):161-3. PMID: 7946146.
      View in: PubMed
    120. Asano T, McWatters A, An T, Matsushima K, Kleinerman ES. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994 Feb; 268(2):1032-9. PMID: 8113959.
      View in: PubMed
    121. Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunol Immunother. 1994 Jan; 38(1):16-22. PMID: 8299114.
      View in: PubMed
    122. Asano T, Fujimaki W, McWatters A, An T, Matsushima K, Kleinerman ES. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother. 1993 Nov; 37(6):408-11. PMID: 8242665.
      View in: PubMed
    123. Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):286-92. PMID: 8280710.
      View in: PubMed
    124. Maeda M, Asano T, Kleinerman ES. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide. Cancer Immunol Immunother. 1993 Aug; 37(3):203-8. PMID: 8334682.
      View in: PubMed
    125. Curley SA, Roh MS, Feig B, Oyedeji C, Kleinerman ES, Klostergaard J. Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26. J Leukoc Biol. 1993 Jun; 53(6):715-21. PMID: 8315355.
      View in: PubMed
    126. Fidler IJ, Kleinerman ES. Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic. Res Immunol. 1993 May; 144(4):284-7; discussion 294-8. PMID: 8378598.
      View in: PubMed
    127. Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol Immunother. 1993; 36(1):45-51. PMID: 8422667.
      View in: PubMed
    128. Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:101-7. PMID: 8096724.
      View in: PubMed
    129. Fujimaki W, Itoh K, An T, Gano JB, Ross MI, Mansfield PF, Balch CM, Augustus LB, Karkevitch DD, Johnston D, et al. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother. 1993; 8(4):307-18. PMID: 7804372.
      View in: PubMed
    130. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992 Aug; 10(8):1310-6. PMID: 1634921.
      View in: PubMed
    131. Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992; 34(4):211-20. PMID: 1537053.
      View in: PubMed
    132. Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res. 1992; 4(10):413-8. PMID: 1292756.
      View in: PubMed
    133. Jia SF, Kleinerman ES. Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines. Lymphokine Cytokine Res. 1991 Aug; 10(4):281-4. PMID: 1932372.
      View in: PubMed
    134. Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991 Feb; 9(2):259-67. PMID: 1988574.
      View in: PubMed
    135. Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 1991; 3(10-11):313-21. PMID: 1722107.
      View in: PubMed
    136. Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, Kurzrock R. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med. 1990 Nov; 89(5):663-72. PMID: 2239986.
      View in: PubMed
    137. Gottlieb RA, Kleinerman ES, O'Brian CA, Tsujimoto S, Cianciolo GJ, Lennarz WJ. Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E. J Immunol. 1990 Oct 15; 145(8):2566-70. PMID: 2212653.
      View in: PubMed
    138. Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Kleinerman ES. Effect of recombinant human interleukin 4 on human monocyte activity. Cancer Res. 1990 Jun 1; 50(11):3154-8. PMID: 2334911.
      View in: PubMed
    139. Sarmiento M, Kleinerman ES. Innate resistance to herpes simplex virus infection. Human lymphocyte and monocyte inhibition of viral replication. J Immunol. 1990 Mar 1; 144(5):1942-53. PMID: 2155270.
      View in: PubMed
    140. Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastasis Rev. 1990 Feb; 8(4):319-51. PMID: 2182211.
      View in: PubMed
    141. Fidler IJ, Nii A, Utsugi T, Brown D, Bakouche O, Kleinerman ES. Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res. 1990; 9(4):449-63. PMID: 2090873.
      View in: PubMed
    142. Curley SA, Roh MS, Kleinerman E, Klostergaard J. Human recombinant macrophage colony stimulating factor activates murine Kupffer cells to a cytotoxic state. Lymphokine Res. 1990; 9(3):355-63. PMID: 2118971.
      View in: PubMed
    143. Kleinerman ES, Jaffe N. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Prog Clin Biol Res. 1990; 343:263-79. PMID: 2198583.
      View in: PubMed
    144. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989 Dec; 7(12):1915-25. PMID: 2479721.
      View in: PubMed
    145. Kleinerman ES, Knowles RD, Blick MB, Zwelling LA. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. J Leukoc Biol. 1989 Nov; 46(5):484-92. PMID: 2553837.
      View in: PubMed
    146. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1989 Aug 15; 49(16):4665-70. PMID: 2787207.
      View in: PubMed
    147. Gottlieb RA, Lennarz WJ, Knowles RD, Cianciolo GJ, Dinarello CA, Lachman LB, Kleinerman ES. Synthetic peptide corresponding to a conserved domain of the retroviral protein p15E blocks IL-1-mediated signal transduction. J Immunol. 1989 Jun 15; 142(12):4321-8. PMID: 2524528.
      View in: PubMed
    148. Shimizu H, Wyatt D, Knowles RD, Bucana CD, Stanbridge EJ, Kleinerman ES. Human monocytes selectively bind to cells expressing the tumorigenic phenotype. Cancer Immunol Immunother. 1989; 28(3):185-92. PMID: 2784354.
      View in: PubMed
    149. Fidler IJ, Nii A, Tsao JY, Davis S, Kleinerman ES. Activated human blood monocytes trigger the antitumor activity of blood polymorphonuclear cells. Lymphokine Res. 1989; 8(4):427-37. PMID: 2811474.
      View in: PubMed
    150. Hudson MM, Snyder JS, Jaffe N, Kleinerman ES. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res. 1988 Sep 15; 48(18):5256-63. PMID: 3261632.
      View in: PubMed
    151. Kleinerman ES, Knowles RD, Lachman LB, Gutterman JU. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res. 1988 May 1; 48(9):2604-9. PMID: 3128401.
      View in: PubMed
    152. Bakouche O, Lachman LB, Knowles RD, Kleinerman ES. Cytotoxic liposomes: membrane interleukin 1 presented in multilamellar vesicles. Lymphokine Res. 1988; 7(4):445-56. PMID: 3264870.
      View in: PubMed
    153. Kleinerman ES, Lachman LB, Knowles RD, Snyderman R, Cianciolo GJ. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. J Immunol. 1987 Oct 1; 139(7):2329-37. PMID: 2821111.
      View in: PubMed
    154. Lachman LB, Bakouche O, Kleinerman ES. Contradictory action of interleukin-1: cell growth and tumour cell killing. Ann Inst Pasteur Immunol. 1987 May-Jun; 138(3):500-4. PMID: 3307835.
      View in: PubMed
    155. Bertoglio JH, Rimsky L, Kleinerman ES, Lachman LB. B-cell line-derived interleukin 1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line. Lymphokine Res. 1987; 6(2):83-91. PMID: 3495709.
      View in: PubMed
    156. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res. 1986 Oct; 46(10):5401-5. PMID: 3093063.
      View in: PubMed
    157. Shimizu H, Jaffe N, Kleinerman E. Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy. J Neurooncol. 1986; 4(2):165-7. PMID: 3023560.
      View in: PubMed
    158. Fidler IJ, Fogler WE, Kleinerman ES, Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. J Immunol. 1985 Dec; 135(6):4289-96. PMID: 3934281.
      View in: PubMed
    159. Saiki I, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJ. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res. 1985 Dec; 45(12 Pt 1):6188-93. PMID: 3933823.
      View in: PubMed
    160. Kleinerman ES, Ceccorulli LM, Zwelling LA, Twilley T, Herberman RB, Jacob J, Gelmann EP. Activation of monocyte-mediated tumoricidal activity in patients with acquired immunodeficiency syndrome. J Clin Oncol. 1985 Jul; 3(7):1005-12. PMID: 3926955.
      View in: PubMed
    161. Onozaki K, Matsushima K, Kleinerman ES, Saito T, Oppenheim JJ. Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity. J Immunol. 1985 Jul; 135(1):314-20. PMID: 3873493.
      View in: PubMed
    162. Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R, Gallin JI. Lysis of tumor cells by human blood monocytes by a mechanism independent of activation of the oxidative burst. Cancer Res. 1985 May; 45(5):2058-64. PMID: 2985242.
      View in: PubMed
    163. Kleinerman ES, Fogler WE, Fidler IJ. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes. J Leukoc Biol. 1985 May; 37(5):571-84. PMID: 3920339.
      View in: PubMed
    164. Koff WC, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocyte-mediated cytotoxicity against herpes simplex virus-infected cells: activation of cytotoxic monocytes by free and liposome-encapsulated lymphokines. J Leukoc Biol. 1985 Apr; 37(4):461-72. PMID: 3882870.
      View in: PubMed
    165. Kleinerman ES, Wiltrout RH, Zicht R, Fidler IJ. Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon. Cancer Immunol Immunother. 1985; 20(2):151-7. PMID: 3930068.
      View in: PubMed
    166. Kleinerman ES, Zicht R, Sarin PS, Gallo RC, Fidler IJ. Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia virus-positive cell line. Cancer Res. 1984 Oct; 44(10):4470-5. PMID: 6088039.
      View in: PubMed
    167. Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol. 1984 Aug; 2(8):937-43. PMID: 6379124.
      View in: PubMed
    168. Kleinerman ES, Herberman RB. Tumoricidal activity of human monocytes: evidence for cytolytic function distinct from that of NK cells. J Immunol. 1984 Jul; 133(1):4-6. PMID: 6373931.
      View in: PubMed
    169. Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science. 1984 Jun 1; 224(4652):1007-9. PMID: 6426057.
      View in: PubMed
    170. Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest. 1983 Jul; 72(1):304-15. PMID: 6348087; PMCID: PMC1129186.
    171. Bucana CD, Hoyer LC, Schroit AJ, Kleinerman E, Fidler IJ. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am J Pathol. 1983 Jul; 112(1):101-11. PMID: 6859224; PMCID: PMC1916313.
    172. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983 May; 43(5):2010-4. PMID: 6831430.
      View in: PubMed
    173. Kleinerman ES, Fidler IJ. Production and utilization of human lymphokines containing macrophage-activating factor (MAF) activity. Lymphokine Res. 1983; 2(1):7-12. PMID: 6381900.
      View in: PubMed
    174. Kleinerman ES, Zwelling LA, Schwartz R, Muchmore AV. Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity. Cancer Res. 1982 May; 42(5):1692-5. PMID: 6896012.
      View in: PubMed
    175. Kleinerman ES, Decker JM, Muchmore AV. In vitro cellular regulation of monocyte function: evidence for a radiosensitive suppressor. J Reticuloendothel Soc. 1981 Nov; 30(5):373-80. PMID: 6459454.
      View in: PubMed
    176. Kleinerman ES, Louie JS, Wahl LM, Muchmore AV. Pharmacology of human spontaneous monocyte-mediated cytotoxicity. I. Enhancement by salicylates and steroids. Arthritis Rheum. 1981 Jun; 24(6):774-80. PMID: 7247974.
      View in: PubMed
    177. Kleinerman ES, Zwelling LA, Howser D, Barlock A, Young RC, Decker JM, Bull J, Muchmore AV. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet. 1980 Nov 22; 2(8204):1102-5. PMID: 6107723.
      View in: PubMed
    178. Kleinerman ES, Zwelling LA, Muchmore AV. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum(II). Cancer Res. 1980 Sep; 40(9):3099-102. PMID: 6448684.
      View in: PubMed
    179. Greenberg LW, Kleinerman E. Neisseria lactamica meningitis. J Pediatr. 1978 Dec; 93(6):1061-2. PMID: 722428.
      View in: PubMed
    180. Daniels CA, Kleinerman ES, Snyderman R. Abortive and productive infections of human mononuclear phagocytes by type I herpes simplex virus. Am J Pathol. 1978 Apr; 91(1):119-36. PMID: 206146; PMCID: PMC2018167.
    181. Kleinerman ES, Daniels CA, Polisson RP, Snyderman R. Effect of virus infection on the inflammatory response. Depression of macrophage accumulation in influenza-infected mice. Am J Pathol. 1976 Nov; 85(2):373-82. PMID: 11695.
      View in: PubMed
    182. Kleinerman ES, Snyderman R, Daniels CA. Depressed monocyte chemotaxis during acute influenza infection. Lancet. 1975 Nov 29; 2(7944):1063-6. PMID: 53552.
      View in: PubMed
    183. Kleinerman ES, Snyderman R, Daniels CA. Depression of human monocyte chemotaxis by herpes simplex and influenza viruses. J Immunol. 1974 Nov; 113(5):1562-7. PMID: 4370991.
      View in: PubMed
    184. Cis-platinum (II)diamminedichloride (PDD) stimulates spontaneous monocyte-mediated cellular cytotoxicity (SMCC).
    185. Osteosarcoma metastatic to the pancreas in young patients. Brain and Language. 51:293-294.
    186. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults. Oncoscience. 1:522-530.
    187. Effect of various cancer chemotherapeutic agents on naturally occurring human spontaneous monocyte-mediated cytotoxicity (SMMC). 1101.
    188. Mifamurtide in metastatic and recurrent osteosarcoma. Pediatric Blood and Cancer. 61:238-244.
    189. Activation of human monocyte-mediated cytotoxicity by liposomes containing human lymphokine.
    190. Cytotoxic liposomes. 149-164.
    191. Current advances in osteosarcoma. Advances in Experimental Medicine and Biology. 804.
    192. The effect of cis-diamminedichloroplatinum (II) on immune function in vitro and in vivo. Cancer Immunology Immunotherapy. 12:191-196.
    193. Current advances in osteosarcoma[Advances in Experimental Medicine and Biology, DOI 10.1007/978-3-319-04843-7_20]. Advances in Experimental Medicine and Biology. 804:1.
    194. Hes4. Pediatric Blood and Cancer.
    195. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of osteosarcoma. Cancer Bulletin. 43:127-132.
    196. Liposome therapy. International Journal of Pediatric Hematology/Oncology. 5:49.
    197. Lack of immunomodulatory interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clinical Cancer Research. 22:3876-3883.
    198. Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis. Advanced Drug Delivery Reviews. 13:325-340.
    199. In reply. Journal of Clinical Oncology. 26:3104-3105.
    200. Effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. Clinics in Immunology and Allergy. 4:279-294.
    201. Human fibroblast interferon inhibits the development of monocyte-mediated cytotoxicity in vitro. Clinical Research. 30.
    202. The Lancet Oncology. 17:1340-1342.
    KLEINERMAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description